Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6697072 | 0.91 | KMT2A (0.39) | KMT2AL3MBTL1MAPK1ACEGPR119 | |
| SCHEMBL6693830 | 0.84 | KMT2A (0.39) | KMT2AL3MBTL1MAPK1ACEMEN1 | |
| SCHEMBL7018946 | 0.83 | KMT2A (0.39) | KMT2AL3MBTL1MAPK1ACEGPR119 | |
| SCHEMBL6699270 | 0.83 | KMT2A (0.39) | KMT2AL3MBTL1MAPK1ACEGPR119 | |
| SCHEMBL6693568 | 0.83 | KMT2A (0.39) | KMT2AL3MBTL1MAPK1ACEGPR119 | |
| SCHEMBL6695450 | 0.83 | KMT2A (0.39) | KMT2AL3MBTL1MAPK1ACEGPR119 | |
| SCHEMBL6698778 | 0.83 | KMT2A (0.37) | KMT2AL3MBTL1MAPK1ACEMEN1 | |
| SCHEMBL6704197 | 0.82 | KMT2A (0.42) | KMT2AL3MBTL1 | |
| SCHEMBL6697245 | 0.81 | SIGMAR1 (0.40) | KMT2AL3MBTL1MAPK1MEN1NPSR1 | |
| SCHEMBL7682461 | 0.80 | KMT2A (0.36) | KMT2AL3MBTL1MAPK1MEN1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831096-B2 | Effective against both A and B forms of influenza; oral bioavailability | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| US-20040097471-A1 | Inhibitors of neuraminidases | ABBVIE INC. | 2004-05-20 | — | — | US | disclosed |
| EP-1358154-A2 | PYRROLIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF NEURAMINIDASES | Abbott Laboratories (US) | 2003-11-05 | — | — | EP | disclosed |
| EP-1315698-A1 | PYRROLIDINES AS INHIBITORS OF NEURAMINIDASES | ABBOTT LABORATORIES (US) | 2003-06-04 | — | — | EP | disclosed |
| US-6455571-B1 | ESPECIALLY, INFLUENZA NEURAMINIDASE. | ABBOTT LABORATORIES | 2002-09-24 | — | — | US | disclosed |
| WO-2001028996-A2 | PYRROLIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF NEURAMINIDASES | ABBOTT LABORATORIES (US) | 2001-04-26 | — | — | WO | disclosed |
| WO-1999054299-A1 | PYRROLIDINES AS INHIBITORS OF NEURAMINIDASES | ABBOTT LABORATORIES (US) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097471-A1 | Inhibitors of neuraminidases | NEU1, NEU2, NEU4 | KMT2A 3372/4885L3MBTL1 3963/4885MAPK1 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.